SPRAVATO Drug Patent Profile

Which patents cover Spravato, and when can generic versions of Spravato launch?

Spravato is a drug marketed by Janssen Pharms and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-two patent family members in twenty-four countries.

The generic ingredient in SPRAVATO is esketamine hydrochloride. One supplier is listed for this compound. Additional details are available on the esketamine hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Spravato

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 17, 2028. This may change due to patent challenges or generic licensing.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for SPRAVATO

International Patents:	62
US Patents:	7
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	18
Clinical Trials:	7
Patent Applications:	202
Drug Prices:	Drug price information for SPRAVATO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SPRAVATO
What excipients (inactive ingredients) are in SPRAVATO?	SPRAVATO excipients list
DailyMed Link:	SPRAVATO at DailyMed

See drug prices for SPRAVATO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for SPRAVATO

Constraining patent/regulatory exclusivity:

EXPANSION OF THE INDICATION TO INCLUDE MONOTHERAPY OF ESKETAMINE FOR TREATMENT-RESISTANTDEPRESSION (TRD)

NDA:

211243

Dosage:

SPRAY;NASAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for SPRAVATO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Yale University	PHASE3
Patient-Centered Outcomes Research Institute	PHASE3
Helsinki University Central Hospital	PHASE1

See all SPRAVATO clinical trials

Paragraph IV (Patent) Challenges for SPRAVATO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SPRAVATO	Nasal Spray	esketamine hydrochloride	28 mg	211243	3	2023-03-06

US Patents and Regulatory Information for SPRAVATO

SPRAVATO is protected by twenty-five US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on EXPANSION OF THE INDICATION TO INCLUDE MONOTHERAPY OF ESKETAMINE FOR TREATMENT-RESISTANTDEPRESSION (TRD).

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	SPRAVATO	esketamine hydrochloride	SPRAY;NASAL	211243-001	Mar 5, 2019		RX	Yes	Yes	8,785,500
Janssen Pharms	SPRAVATO	esketamine hydrochloride	SPRAY;NASAL	211243-001	Mar 5, 2019		RX	Yes	Yes	11,173,134
Janssen Pharms	SPRAVATO	esketamine hydrochloride	SPRAY;NASAL	211243-001	Mar 5, 2019		RX	Yes	Yes	9,592,207

International Patents for SPRAVATO

When does loss-of-exclusivity occur for SPRAVATO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

China

European Patent Office

Japan

South Korea

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SPRAVATO around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2015318123	Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression
Canada	2961208	REGIMES POSOLOGIQUES SPECIFIQUES AU GENOTYPE VAL66MET (SNP RS6265) ET METHODES POUR LE TRAITEMENT DE LA DEPRESSION (VAL66MET (SNP RS6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION)
China	107208133	用于治疗抑郁症的Val66Met (SNPrs6265)基因型特异性给药方案和方法 (Val66met (snp rs6265) genotype specific dosing regimens and methods for the treatment of depression)

SPRVATO Market Dynamics and Financial Trajectory: Pricing, Growth Drivers, Exclusivity Timeline, and Competitive Risk

Last updated: May 23, 2026

Executive summary: Spravato (esketamine nasal spray) generated sustained high-margin revenue in the US through controlled distribution, REMS restrictions, payor contracting, and limited generic competition. Near-term market dynamics are shaped by (1) persistent payer and site-of-care management for treatment-resistant depression (TRD) and major depressive disorder with acute suicidal ideation or behavior (MDD with SI/SA), (2) utilization trends driven by ketamine education and clinic workflows, and (3) exclusivity and patent risks that govern when lower-cost alternatives could enter. The financial trajectory has tracked dosing intensity, adherence to REMS, and dose adjustments, with revenue volatility tied to insurance coverage breadth, patient mix, and compounding of real-world persistence with conversion from initiation to maintenance.

---

How is Spravato marketed in the US and what drives utilization economics?

Spravato is marketed for two FDA-approved indications:

• Treatment-resistant depression (TRD)
• Major depressive disorder with acute suicidal ideation or behavior (MDD with SI/SA)

What is the US commercial model for Spravato under REMS?

Spravato operates under a Risk Evaluation and Mitigation Strategy (REMS) that restricts dispensing to certified sites and requires administration under healthcare supervision. This creates a distribution funnel that typically reduces retail-style diffusion and concentrates volume among clinics that can operationalize REMS workflows. Key commercial implications:

• Patient acquisition costs stay elevated because prescriber conversion requires training and referral networks.
• Site of care capacity constrains throughput, which can cap near-term revenue growth even when demand exists.
• Improves payer predictability through structured administration, but increases administrative friction for contracting and claim adjudication.

What are the revenue drivers by dose pattern and treatment stage?

Revenue is driven by:

• Initiation dosing (induction phase)
• Maintenance dosing frequency
• Dose changes (90 mg vs. 56 mg dosing pathways used in practice)
• Resupply cadence in certified sites

Operationally, the highest revenue concentration occurs during early lines of therapy and during patients who remain on maintenance. Financial trajectory is therefore sensitive to:

• Proportion of patients who remain on therapy past early response assessments
• Rate of discontinuation due to response dropout, tolerability, or payer-driven limits
• Share of prescriptions that convert from specialist evaluation to consistent REMS administration

---

What patents protect Spravato and how many years of exclusivity remain?

Spravato is protected by a combination of composition-of-matter, formulation, and method-of-treatment/patent estate components typical for specialty CNS delivery products. Exclusivity and patent protection structure matters because REMS can slow generic substitution even after legal entry, meaning the effective competitive timeline depends on both patent expiry and the ability of generics to launch with REMS-compatible operations.

How long does exclusivity typically delay generic and biosimilar competition for esketamine nasal spray?

For small-molecule products like esketamine, exclusivity typically includes:

• US regulatory exclusivities (new chemical entity and/or pediatric exclusivity)
• Patent exclusivity (composition and use claims)

Because generic entry depends on Paragraph IV certifications and patent landscape clearing, the market often experiences a staged shift:

1. Legal threat builds (generic filings, litigation)
2. Litigation and settlement define “launch date uncertainty”
3. Post-expiry, branded revenue declines gradually if dosing equivalents and patient acceptance are maintained

---

What formulations and method-of-use patents affect Spravato’s competitive freedom?

Even when composition-of-matter protection ends, method-of-use claims tied to TRD or SI/SA regimens can delay “skinny” or design-around entry.

Which patent buckets typically block generic esketamine nasal spray?

• Composition and crystalline form claims for esketamine
• Formulation patents for nasal delivery
• Method-of-use patents for TRD response monitoring and maintenance schedule
• Patient selection claims tied to TRD definition thresholds or acute SI/SA workflow

If method-of-use patents are still active, generics may attempt to enter but face carve-outs that preserve branded coverage for protected regimens, limiting competitive impact.

---

What Orange Book status does Spravato have and what does it imply for generic entry risks?

The Orange Book listings indicate:

• Listed patents with expiration dates
• Patent numbers that may be subject to Paragraph IV challenges
• Barriers to generic launch for specific dosage forms (nasal spray)

What Orange Book structure matters for market timing?

• If only a subset of patents expires earlier, launch timing can be pushed to the last listed blocking patent.
• If patent concentration is heavy on method-of-use, generics can face reduced commercial viability even after legal permission.
• Orange Book “thinness” by jurisdiction is rarely uniform: US patent expiration can align poorly with the ability to secure payer coverage or handle REMS operations.

---

Have generic companies challenged Spravato via Paragraph IV and what litigation shaped launch timing?

Paragraph IV challenges (Abbreviated New Drug Application certifications) drive the largest step-changes in generic threat. Litigation and settlements determine whether:

• Multiple challengers coordinate to share risk
• A first challenger triggers a “base” settlement that delays other entrants
• Carve-outs allow partial substitution

What litigation and settlement patterns usually govern esketamine nasal spray?

Specialty CNS products with REMS commonly see:

• Settlement agreements that impose staggered launch dates
• Restrictions on marketing or labeling that align with method-of-use or formulation protection
• Dismissals or stay agreements that preserve brand market share

---

How does Spravato’s financial trajectory compare with other CNS specialty products under REMS or REMS-like controls?

Spravato’s market resembles other restricted distribution CNS therapies in three ways:

• Growth depends on provider network density and training
• Payer contracting and utilization management drive adoption more than pure drug efficacy headlines
• Revenue has a “site ramp” shape, not an instantaneous substitution shape

What matters more than price alone in CNS specialty revenue?

• Treatment persistence and maintenance coverage
• Claim acceptance and prior authorization approval rates
• Channel mix (specialty clinics vs. hospital-based outpatient)
• Dose intensity and titration practices

As a result, even when unit pricing stays high, revenue outcomes can track changes in coverage policy and discontinuation.

---

What is the competitive landscape for Spravato: branded vs. generic entry and payer dynamics?

Competitive pressure for Spravato usually comes from three fronts:

1. Patent-driven generic entry risk (labeled product substitution)
2. Off-label or alternative intranasal/IV ketamine strategies at the clinic level
3. Product and payer contracting that steers patients toward covered regimens

How do payers manage Spravato coverage in practice?

Payers often use combinations of:

• Step therapy requirements
• TRD documentation rules (prior failures)
• Quantity limits or visit-based limits
• Prior authorization with outcome criteria after early response windows

These controls cap near-term volume even when eligible patient populations exist.

How does clinic administration affect competitive substitution after legal entry?

REMS certification and administration workflow can make substitution slower than legal entry dates imply:

• Clinics may keep branded stock to reduce operational risk
• Pharmacist substitution processes are slower when administration must be supervised
• Patients may resist switching for tolerability reasons, especially when they have stable response

---

When does Spravato lose exclusivity and when could revenue be pressured by generic launches?

Revenue pressure usually begins before the first generic launch as expectations shift, and becomes more visible at:

• The first permitted generic supply that is practically integrated into REMS-certified workflows
• Contracting shifts that reduce branded net price
• Payer policy changes that widen substitution eligibility

What are the market timing milestones to monitor?

• Orange Book expiration date of the last blocking patent
• Paragraph IV litigation resolution or settlement effective date
• FDA approval timing for generic labeling and device/nasal spray specs
• REMS operational readiness and supply ramp at certified sites

---

What FDA regulatory status and manufacturing/IP barriers influence Spravato’s market outlook?

Regulatory and manufacturing risks affect both brand continuity and the credibility of generic launch readiness.

What regulatory factors matter most for esketamine nasal spray?

• Label alignment for TRD and SI/SA dosing regimens
• Bioequivalence and formulation consistency for nasal delivery
• Stability and device delivery performance
• Post-marketing compliance that affects supply continuity

What IP or CMC issues can still slow generic entry even after patent expiry?

Even with patent clearance, manufacturing and formulation equivalency can delay:

• Scale-up and batch consistency
• Nasal spray performance validation
• REMS program integration at manufacturing and distribution levels

In practice, these can compress or extend launch windows versus the patent calendar.

---

Commercial forecast drivers: how do dosing, persistence, and net price change Spravato revenue?

A financial trajectory for Spravato is best modeled through:

• New patient starts (TRD, SI/SA)
• Dose utilization per patient (induction to maintenance conversion)
• Persistence and discontinuation
• Net price under payor contracting and rebates
• Patient mix (specialty vs. general mental health referral patterns)

What is the revenue sensitivity order for specialty nasal CNS products?

Typically:

1. Persistence and maintenance share
2. Net price and payer coverage breadth
3. Starts volume and conversion rate into REMS-capable sites
4. Dose intensity and adherence to protocol
5. Channel and geographic expansion pace

---

Key financial and market dynamics checklist for Spravato investors and licensors

• Channel constraint: REMS certified sites limit immediate scaling even if prescriber interest is high.
• Payer contracting risk: Net price can compress without unit volume changes.
• Patent calendar risk: The last blocking patent among Orange Book listed patents is the effective generic barrier.
• Litigation/settlement lock-in: Settlements often define a “real” launch date rather than the raw expiration.
• Switching friction: Even after legal entry, workflow and patient tolerability slow substitution.
• Indication mix: TRD vs. SI/SA conversion impacts dose intensity and persistence.

---

Key Takeaways

• Spravato’s market dynamics are dominated by REMS-enabled administration constraints, payer utilization management, and persistence-driven dosing economics.
• The financial trajectory is highly sensitive to patient maintenance share, coverage policy, and dosing adherence after induction.
• Generic entry risk is governed by Orange Book blocking patents and the litigation/settlement path, not only by the headline exclusivity end date.
• Even after legal entry, operational REMS integration and clinic adoption can delay meaningful revenue erosion compared with purely patent-calendar expectations.

---

FAQs

1) What non-patent factors slow generic substitution for Spravato even after legal entry?

REMS administration workflow, clinic stocking behavior, prior authorization and coverage rules, and patient switching reluctance.

2) How do TRD and acute SI/SA indications differ in market growth and pricing pressure?

TRD typically drives longer-course maintenance economics; acute SI/SA can concentrate utilization around urgent care workflows with faster churn and different payer authorization mechanics.

3) What Orange Book patent categories most often determine Spravato’s effective launch date for generics?

Method-of-use and formulation patents that remain listed and can sustain labeling or regimen carve-outs that limit generic substitution.

4) What settlement agreement terms usually matter for future generic launch timing?

Staggered launch dates, marketing and labeling carve-outs, and stays/dismissals that bind challengers and adjacent filers.

5) What manufacturing/CMC risks are most relevant for nasal esketamine generics?

Nasal delivery consistency, bioequivalence for locally delivered formulations, stability across storage and shipping, and reliable spray performance.

---

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
2. U.S. Food and Drug Administration. Esketamine nasal spray prescribing information and REMS documentation.
3. FDA. Drug Approval Packages and Labeling for Spravato (esketamine).
4. FDA. Guidance for Industry: ANDAs and Paragraph IV certification framework.

DrugChatter Q&A for SPRAVATO

Spravato ema approval date?
Spravato nasal spray cost?
Spravato sales revenue market share 2025 2026?
Spravato marketing services?
Ema spravato epar product information 2024?